Switzerland remains a global leader in life sciences in 2025, supported by political stability, a strong regulatory framework and a highly skilled scientific workforce. As other markets face growing uncertainty, Switzerland continues to attract both investment and talent, reinforcing its position as a hub for innovation and drug development.
The sector is going through a quiet but important shift. While late-stage pharma still leads the way, there’s a clear move towards early-stage biotech driven by looming patent cliffs, increasing AI adoption, and shifting investor priorities. This change is reflected in hiring data: demand for scientists is rising with a growing focus on R&D, lab-based roles, and quality control.
Global pressures are only accelerating this trend. From new drug pricing policies in the US to a tougher funding climate for biotech, companies are rethinking how and where they scale. In this context, Switzerland has become a standout option: stable and well-positioned for growth.
This report takes a closer look at hiring across Swiss life sciences in 2025, exploring regional trends, sector shifts and what they tell us about where the industry is heading.
Click here for the full range of reports
For the full report Click Here
Roma Aleinikav - Consultant